Atlas Trials

The Netherlands Cancer Institute

228 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch The Netherlands Cancer Institute

RecordFirmDate
Dedicated MR Imaging vs Surgical Staging of Peritoneal Carcinomatosis in Colorectal Cancer (NCT04231175)The Netherlands Cancer Institute2019-10-28
Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN) (NCT04017455)The Netherlands Cancer Institute2019-10-22
Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO (NCT03815890)The Netherlands Cancer Institute2019-10-04
Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed. (NCT04737382)The Netherlands Cancer Institute2019-08-22
Internet-based WOrk-related Cognitive Rehabilitation for Cancer Survivors: a Randomized Controlled Trial (NCT03900806)The Netherlands Cancer Institute2019-08-03
Lymph Drainage Mapping for Tailoring Elective Nodal Irradiation in Head and Neck Cancer (NCT03968679)The Netherlands Cancer Institute2019-07-22
ctDNA Guided Treatment of Early Resistance to Targeted Treatment (NCT04148066)The Netherlands Cancer Institute2019-07-17
Improve Checkpoint-blockade Response in Advanced Urothelial Cancer (NCT03871036)The Netherlands Cancer Institute2019-05-01
Health-related Quality of Life and Late Effects Among SURVivors of Cancer in Adolescence and Young Adulthood: The SURVAYA Study (NCT05379387)The Netherlands Cancer Institute2019-05-01
Assessing Health-related Quality of Life in Sarcoma Patients (NCT04071704)The Netherlands Cancer Institute2019-05-01
Health After eaRly Menopause Due to Oophorectomy (NCT03835793)The Netherlands Cancer Institute2019-02-11
Blood Sampling of Healthy Volunteers for Immunological Research (NCT03819829)The Netherlands Cancer Institute2019-02-05
The MR-Linac Technical Feasibility Protocol (NCT04351204)The Netherlands Cancer Institute2019-01-22
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment (NCT04287894)The Netherlands Cancer Institute2018-12-28
T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC (NCT03784599)The Netherlands Cancer Institute2018-12-18
Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer (NCT03727724)The Netherlands Cancer Institute2018-12-04
Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NCT03852979)The Netherlands Cancer Institute2018-11-01
18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC (NCT03564197)The Netherlands Cancer Institute2018-10-25
PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study (NCT03686332)The Netherlands Cancer Institute2018-09-25
Sentinel Lymph Node Procedure in Testicular Germ Cell Tumour (NCT03448822)The Netherlands Cancer Institute2018-09-01
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (NCT03470350)The Netherlands Cancer Institute2018-08-24
ctDNA as a Biomarker for Treatment Response in HNSCC (NCT03540563)The Netherlands Cancer Institute2018-07-16
A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients (NCT02826512)The Netherlands Cancer Institute2018-05-15
Clinical Impact of Dedicated MR Staging of Ovarian Cancer (NCT03399344)The Netherlands Cancer Institute2018-04-13
Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC (NCT03341845)The Netherlands Cancer Institute2018-03-28
Preoperative Breast Irradiation (NCT02941835)The Netherlands Cancer Institute2018-03-12
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA) (NCT03448835)The Netherlands Cancer Institute2018-03-07
Vinorelbine in Advanced BRAF-like Colon Cancer (NCT03482362)The Netherlands Cancer Institute2018-03-01
Early Response Evaluation in NSCLC Patients Treated With Immunotherapy (NCT04082988)The Netherlands Cancer Institute2018-01-23
Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NCT03387761)The Netherlands Cancer Institute2018-01-15
Monitoring MRI Changes Before and During Radiotherapy Treatment of Brain Tumors (NCT03394716)The Netherlands Cancer Institute2018-01-12
Multicentric Randomised Trial for Resectable Gastric Cancer (NCT02931890)The Netherlands Cancer Institute2017-12-21
Adaptive Dose-Escalated Multi-modality Image-guided RadiothErapy (NCT03376386)The Netherlands Cancer Institute2017-12-21
Dose-Effect Relation of Salivary Gland Irradiation (NCT03367780)The Netherlands Cancer Institute2017-11-21
AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer (NCT03147040)The Netherlands Cancer Institute2017-11-02
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer (NCT03126812)The Netherlands Cancer Institute2017-11-01
Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC (NCT02947113)The Netherlands Cancer Institute2017-11-01
Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination. (NCT03348150)The Netherlands Cancer Institute2017-10-01
To Decrease Fatigue With Light Therapy (NCT03242902)The Netherlands Cancer Institute2017-09-20
A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS) (NCT02910895)The Netherlands Cancer Institute2017-09-09
The Impact of a Web-based Patient Decision Aid for Women Considering Breast Reconstruction (NCT03791138)The Netherlands Cancer Institute2017-08-16
"Wait-and-see" Policy for Complete Responders After Chemoradiotherapy for Rectal Cancer (NCT03426397)The Netherlands Cancer Institute2017-05-10
Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel (NCT03295565)The Netherlands Cancer Institute2017-05-07
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (NCT03026140)The Netherlands Cancer Institute2017-03-29
ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma (NCT03003637)The Netherlands Cancer Institute2017-02-28
Management of Low-risk (Grade I and II) DCIS (NCT02492607)The Netherlands Cancer Institute2017-02-13
Bioimmunoradiotherapy (Cetuximab/RT/Avelumab) (NCT02938273)The Netherlands Cancer Institute2017-02-01
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer (NCT02810743)The Netherlands Cancer Institute2017-01-25
Navigated Abdominal Lymph Node Dissections (NCT05867095)The Netherlands Cancer Institute2017-01-24
Carboplatin-cyclophosphamide Combined With Atezolizumab (NCT02914470)The Netherlands Cancer Institute2017-01-01
Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (NCT02437279)The Netherlands Cancer Institute2016-11-24
Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (NCT02977052)The Netherlands Cancer Institute2016-11-24
Pre- Versus Postoperative Accelerated Partial Breast Irradiation (NCT02913729)The Netherlands Cancer Institute2016-11-10
Dexamphetamine Sustained Release Pharmacokinetics and Clinical Validation of Dried Blood Spots (NCT02768441)The Netherlands Cancer Institute2016-11-01
The Effectiveness of Patient Navigation in Cancer Care (NCT03305965)The Netherlands Cancer Institute2016-10-15
Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma (NCT02775006)The Netherlands Cancer Institute2016-10-14
Study With Improved Solubility Pazopanib (NCT02810756)The Netherlands Cancer Institute2016-09-15
Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer (NCT03066154)The Netherlands Cancer Institute2016-09-01
The Development of a Personalized Decision Aid: Perspectives of Patients and Health Care Professionals on Shared Decision Making and Informational Needs on Radiotherapy for Breast Cancer (NCT02934126)The Netherlands Cancer Institute2016-09-01
Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma (NCT03048474)The Netherlands Cancer Institute2016-09-01
The Drug Rediscovery Protocol (DRUP Trial) (NCT02925234)The Netherlands Cancer Institute2016-08-01
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma (NCT02836548)The Netherlands Cancer Institute2016-06-01
Lung Cancer Early Molecular Assessment Trial (NCT02894853)The Netherlands Cancer Institute2016-06-01
Food-effect Study on Uracil and Dihydrouracil Levels as a Diagnostic Marker of Dihydropyrimidine Dehydrogenase Activity (NCT02718664)The Netherlands Cancer Institute2016-04-14
Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer (NCT02743923)The Netherlands Cancer Institute2016-04-01
Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin (NCT02695459)The Netherlands Cancer Institute2016-03-30
Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients (NCT02575066)The Netherlands Cancer Institute2016-03-17
Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients (NCT02625337)The Netherlands Cancer Institute2016-01-01
Comparing Two Palliative Schemes of Radiotherapy for Head and Neck Cancer (NCT02421458)The Netherlands Cancer Institute2015-11-01
Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223 (NCT03223727)The Netherlands Cancer Institute2015-10-30
Molecular Stool Testing for Colorectal Cancer Surveillance (NCT02715141)The Netherlands Cancer Institute2015-10-01
Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients (NCT02499367)The Netherlands Cancer Institute2015-08-01
Mapping of Sentinel Lymph Node Drainage Using SPECT (SUSPECT) (SUSPECT) (NCT02572661)The Netherlands Cancer Institute2015-07-23
Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC (NCT02492568)The Netherlands Cancer Institute2015-07-01
Nivolumab in Patients With Recurrent Malignant Mesothelioma (NCT02497508)The Netherlands Cancer Institute2015-07-01
Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer (NCT02450656)The Netherlands Cancer Institute2015-06-01
Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer (NCT02418624)The Netherlands Cancer Institute2015-05-01
Identifying Subgroups With High Cardiovascular Risk in Breast Cancer Survivors (NCT02485626)The Netherlands Cancer Institute2015-04-01
Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines (NCT02324452)The Netherlands Cancer Institute2015-03-01
Internet-based Cognitive Behavioral Therapy for Breast Cancer Patients With Climacteric Symptoms (NCT02672189)The Netherlands Cancer Institute2015-02-01
Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223 (NCT03223597)The Netherlands Cancer Institute2015-01-17
Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen (NCT02285179)The Netherlands Cancer Institute2014-11-01
Lapatinib Plus Trametinib in KRAS Mutant NSCLC (NCT02230553)The Netherlands Cancer Institute2014-10-07
Olaparib and Radiotherapy in Head and Neck Cancer (NCT02229656)The Netherlands Cancer Institute2014-09-24
Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma (NCT02278887)The Netherlands Cancer Institute2014-09-23
An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income Countries (NCT02247713)The Netherlands Cancer Institute2014-09-01
High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer (NCT01646034)The Netherlands Cancer Institute2014-09-01
Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation (NCT03297385)The Netherlands Cancer Institute2014-08-28
4D FDG PET in Esophageal Cancer (NCT02424864)The Netherlands Cancer Institute2014-08-01
Organ Motion and Early Tumor Response Measurement (NCT02139488)The Netherlands Cancer Institute2014-04-18
Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC (NCT02039336)The Netherlands Cancer Institute2014-04-02
Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (NCT01996267)The Netherlands Cancer Institute2013-12-01
Olaparib and Radiotherapy in Inoperable Breast Cancer (NCT02227082)The Netherlands Cancer Institute2013-10-21
Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases (NCT01818713)The Netherlands Cancer Institute2013-10-01
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer (NCT01898117)The Netherlands Cancer Institute2013-07-01
Hippocampus Avoidance PCI vs PCI (NCT01780675)The Netherlands Cancer Institute2013-04-01
PET Response During Chemoradiation of Lung Cancer (NCT02315053)The Netherlands Cancer Institute2013-03-21
Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm. (NCT01933568)The Netherlands Cancer Institute2013-02-28
RCT of an Internet-based CBT Program for Sexuality and Intimacy Problems in Women Treated for Breast Cancer (NCT02091765)The Netherlands Cancer Institute2012-12-01
Adaptive Radiation Treatment for Head and Neck Cancer (NCT01504815)The Netherlands Cancer Institute2012-09-07
← Previous Next →

Track The Netherlands Cancer Institute automatically

Every clearance here is in the API, with alerts when new ones post.